These proof-of-concept studies may facilitate future clinical trials that will be required to determine therapeutic effects improving CFTR function and airway surface hydration on mucus obstruction, airway inflammation and emphysema in patients with COPD. The gene discussed is CFTR; the disease is inflammatory response.